|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||29.23 - 30.25|
|52-week range||11.49 - 33.94|
|PE ratio (TTM)||N/A|
|Earnings date||21 Feb 2018 - 26 Feb 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||40.00|
Interim results from INS-312 show that 28% of patients who previously received 6 months of guideline based therapy (GBT) alone achieved culture conversion following addition of ALIS to therapy, consistent with data from the INS-212 studyContinued treatment of culture positive patients with ALIS + GBT beyond 6 months results in additional patients achieving culture conversion Long-term data from the INS-212 study show that durability of culture conversion is substantially higher among patients treated with ALIS + GBTCompany targeting submission of NDA before the end of MarchRegulatory ...
U.S. stocks climbed on Tuesday as producer prices rose ahead of the Federal Reserve's interest rate decision on Wednesday. The S&P 500 rose 0.2%, while the Dow Jones Industrial Average gained 0.5%. The ...
Insmed Incorporated (INSM) needs investors to pay close attention to the stock based on moves in the options market lately.
On a per-share basis, the Bridgewater, New Jersey-based company said it had a loss of 69 cents. The results matched Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...
Insmed, maker of the new drug Alis, said it will use the proceeds of the stock offering to push the medication to market.